MapLight Therapeutics, Inc. MPLT Clinical Trial — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about MapLight Therapeutics, Inc. 's clinical trial — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MapLight Therapeutics, Inc. 's clinical trial — research and development expense?
- MapLight Therapeutics, Inc. (MPLT) reported clinical trial — research and development expense of $24.82M in Q1 2026.
- How has MapLight Therapeutics, Inc. 's clinical trial — research and development expense changed year-over-year?
- MapLight Therapeutics, Inc. 's clinical trial — research and development expense increased by 1180.0% year-over-year, from $1.94M to $24.82M.
- What does clinical trial — research and development expense mean?
- This metric represents the total costs incurred by the company specifically attributed to the research and development activities within its clinical trial segment. It captures expenditures related to drug discovery, preclinical studies, and the execution of clinical trials for therapeutic candidates. Monitoring this expense provides insight into the company's investment intensity in its pipeline development and its commitment to advancing clinical-stage assets toward regulatory approval.